Background Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in diabetic patients. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed as antihyperglycemic agents, have demonstrated significant cardiovascular benefits beyond glucose control. These agents have been shown to improve heart failure outcomes, reduce atherosclerotic cardiovascular events, and lower overall mortality in diabetic patients. However, the precise mechanisms underlying these benefits and their long-term impact on diverse patient populations require further investigation. Objective This study aims to evaluate the cardiovascular benefits of SGLT2 inhibitors in diabetic patients by analyzing their effects on heart failure hospitalizations, major adverse cardiovascular events (MACE), and overall survival. Additionally, the study explores the potential mechanisms, including hemodynamic, metabolic, and anti-inflammatory pathways, through which these drugs exert their protective effects. Methods A prospective, multicenter randomized controlled trial (RCT) was conducted, enrolling 5,000 diabetic patients with either established CVD or high cardiovascular risk. Participants were randomly assigned to receive either an SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) or a placebo. The study duration was 36 months, with quarterly follow-ups to assess cardiovascular outcomes, renal function, and metabolic parameters. The primary endpoints included the incidence of MACE (composite of myocardial infarction, stroke, and cardiovascular death) and hospitalization for heart failure (HHF). Secondary endpoints included renal function decline, blood pressure changes, and adverse events. Mechanistic assessments included biomarker analysis for inflammatory markers and arterial stiffness measurements. Results At the end of the study period, patients receiving SGLT2 inhibitors exhibited a significant 32% reduction in HHF (HR 0.68, 95% CI 0.60–0.76, p < 0.001). MACE incidence was reduced by 16% overall, with empagliflozin showing the most pronounced effect (HR 0.86, 95% CI 0.75– 0.98, p = 0.02). A 12% reduction in all-cause mortality was observed (HR 0.88, 95% CI 0.79– 0.97, p = 0.01). Renal outcomes also improved significantly, with a 25% lower risk of progression to end-stage kidney disease in the treatment group (p < 0.01). Mechanistic analyses suggested that SGLT2 inhibitors led to decreased intravascular volume, lower arterial stiffness (mean reduction of 10%), and reduced inflammatory marker levels, contributing to cardiovascular benefits. Adverse events included a higher incidence of genitourinary infections (6% vs. 2% in placebo, p < 0.05) and rare cases of euglycemic ketoacidosis (0.8%). Conclusion This study provides robust evidence that SGLT2 inhibitors significantly improve cardiovascular outcomes in diabetic patients, with notable reductions in heart failure hospitalizations, MACE, and mortality. The findings underscore the multifaceted mechanisms of these agents, supporting their broader role in cardiovascular risk reduction beyond glucose control. Further long-term studies are warranted to explore their effects across diverse patient populations.